>99% Purity
Selank
Nootropic peptide with GABAergic modulation — developed by the Russian Academy of Sciences
€35–€108 EUR
View Product
>99% Purity EU Warehouse
Semax
ACTH(4-10) analogue with BDNF/NGF modulation — 20+ years of published research
Select Quantity
Secure checkout via Peptide-Pay · Visa, Mastercard, Apple Pay, SEPA
Temperature: -20°C (lyophilised) / 2–8°C (solution)
Conditions: Protect from light
Shelf Life: 24 months (lyophilised)
Research Profile
Semax is a synthetic heptapeptide analogue of ACTH(4-10) (sequence Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics, Russian Academy of Sciences. Unlike ACTH, Semax lacks adrenocorticotropic activity. Research focus centres on its neurotropic properties: it upregulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), promotes hippocampal neuroplasticity, and has demonstrated neuroprotective effects in ischaemia models. The peptide is registered as a pharmaceutical in Russia for neurological applications. Outside Russia, it is a research compound with a substantial body of published literature.
Key Research Findings
- ACTH(4-10) analogue without adrenocorticotropic activity
- Upregulates BDNF and NGF expression in hippocampal tissue
- Neuroprotective effects documented in cerebral ischaemia rodent models
- Modulates dopamine and serotonin receptor sensitivity
- Registered pharmaceutical in Russia — 20+ years published research
Miasoedov N.F. et al., Institute of Molecular Genetics, Russian Academy of Sciences. 20+ years of published research including ischaemia models, BDNF upregulation studies, and cognitive performance assays in rodents.
Related Research Compounds
>99% Purity
NAD+
Coenzyme in 500+ enzymatic reactions — longevity research published in Cell and Nature
€85–€230 EUR
View Product